A Phase 2a, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel- Group Study To Evaluate The Safety, Tolerability, And Pharmacodynamics Of Pf-06835919 Administered Once Daily For 6 Weeks In Adults With Nonalcoholic Fatty Liver Disease
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs PF 06835919 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Oct 2017 Planned End Date changed from 1 May 2018 to 13 Jun 2018.
- 06 Oct 2017 Planned primary completion date changed from 1 May 2018 to 13 Jun 2018.
- 06 Oct 2017 Status changed from not yet recruiting to recruiting.